Submitted by Anonymous (not verified) on 20 November 2023 - 11:00
Human medicines European public assessment report (EPAR): Vyepti, eptinezumab, Migraine Disorders, Date of authorisation: 24/01/2022, Revision: 3, Status: Authorised
Source: